Spermidine for Health & Longevity - Quick Reference Sheet

Spermidine for Health & Longevity

Created on 08/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A food-derived molecule that helps cells recycle worn parts. The case rests on animal lifespan work and population studies tying spermidine-rich eating to longer survival and lower blood pressure; a large Japanese population found nothing and hinted at more cancer deaths in women. Swallowed spermidine does not raise blood levels, so tissue delivery is unresolved. (Full Review)

Protocol

Standard supplemental dose
1–6 mg daily
Spermidine from wheat germ extract, taken continuously. The European novel-food authorisation caps intake from this source at about 6 mg spermidine per day.
Best time of day
Morning, with food
Taken with the first meal in trials. Every published trial used one daily dose; no trial has compared timings.
Food-first route
Wheat germ, natto, aged cheese
With mushrooms, peas and whole grains, these push habitual intake from a typical 7–12 mg toward the top intake tier seen in cohort studies.
Time to effect
All-cause mortality
Decades
The mortality evidence reflects decades of habitual intake rather than a supplementation period.
Memory performance
3 months
Nothing measurable in weeks. Trials that saw cognitive change measured it at three months.
Vaccine antibody response
13 weeks
The vaccine pilot measured its outcome at thirteen weeks, in poor responders only.

Benefits

Contraindications
  • Active malignancy under treatment, or cancer treated within the past 12 months
  • Eflornithine (difluoromethylornithine)
  • Prescribed polyamine-restricted diets
  • Biopsy-confirmed celiac disease or immunoglobulin E-mediated wheat allergy (any wheat-germ-derived product)
  • Advanced kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m², or dialysis)
  • Pregnancy and breastfeeding, and anyone under 18
Key Interactions
  • Antihypertensive prescription drugs (ramipril, losartan, amlodipine)
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine)
  • Autophagy-blocking medicines (hydroxychloroquine, chloroquine)
  • Rapamycin and other autophagy-inducing agents
  • Blood-pressure-lowering supplements (dietary nitrate, garlic extract, magnesium, hibiscus, high-dose omega-3)
  • Autophagy and mitophagy supplements (urolithin A, resveratrol, green tea catechins)
  • Diamine oxidase supplements and low-histamine protocols

Risk & Side Effects

  • High: [risks_high]
  • Medium: Support of existing tumour growth — conflicted; wheat and gluten exposure from wheat germ extracts
  • Low: Gastrointestinal discomfort; additive blood-pressure lowering
  • Speculative: Oxidative by-products of polyamine breakdown; accumulation in advanced kidney disease; histamine and biogenic amine load

Monitoring

Marker Target Why
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammation signal seen in exploratory trial analyses
Ambulatory blood pressure, 24 hours Below 120/75 mmHg daytime mean The one cardiovascular endpoint with both an animal and an observational signal
Estimated glomerular filtration rate At or above 90 mL/min/1.73 m² Confirms the renal clearance route for acetylated polyamines is intact
Alanine aminotransferase 10–26 U/L in men, 8–22 U/L in women Standard safety monitoring, matching the trial panels
Fasting insulin 2–5 µIU/mL Captures the metabolic domain where preclinical claims are strongest
Triglyceride to HDL cholesterol ratio Below 1.5 (mg/dL units) Practical readout of the lipid handling claimed from rodent work
Complete blood count Within laboratory reference limits, stable against own baseline Detects any marrow or immune effect of a compound that drives cell proliferation
Homocysteine 5–7 µmol/L Polyamine synthesis consumes the body's main methyl donor, so heavy flux could show here
Plasma spermidine No established target, and it does not rise with supplementation; track change from personal baseline instead Documents the central pharmacokinetic problem rather than a treatment goal
Tissue transglutaminase IgA Negative Screens for celiac disease before committing to a wheat-germ product

Cadence: Baseline before starting, then the safety panel at 3 months, at 12 months, then every 12 months while use continues. Blood pressure: home checks twice daily for the first two weeks in anyone on antihypertensives, then monthly.

Qualitative Assessment

  • Word-finding and name recall in conversation, the everyday version of the trial memory tasks
  • Recovery after infections or vaccinations, given the immune signal in poor responders
  • Daytime energy and afternoon alertness
  • Sleep continuity and how rested mornings feel
  • Hair shedding noticed on brushing or in the shower
  • Digestive comfort in the first weeks, the most commonly reported complaint